It’s a short and dramatic plunge for Achaogen (NASDAQ:AKAO). Today, the drug maker’s shares lost nearly 24% following the news that the FDA …
Cowen’s Chris Shibutani pinpoints enticing commercial prospects ahead for AKAO’s plazomicin.
It’s a short and dramatic plunge for Achaogen (NASDAQ:AKAO). Today, the drug maker’s shares lost 25% of their value following the news that …
Cowen’s Chris Shibutani remains confident on AKAO as he angles for plazomicin’s timely approval in cUTI by the end of June.
Cowen’s Chris Shibutani likes AKAO’s risk-reward set up ahead of today’s AdCom Meeting review of plazomicin.
H.C.
Will the FDA writing on the wall bode well for three pharmaceutical firms raring for a PDUFA nod this summer? Achaogen (NASDAQ:AKAO) complicated …
